TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06002971

Intervention type: DEVICE
Intervention: Blood pressure measurement
Description: Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.

Intervention type: DEVICE
Intervention: Blood pressure measurement
Description: Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.

Intervention type: DEVICE
Intervention: Blood pressure measurement
Description: Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.
Study: NCT05029401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMX-1002
Description: Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to the IMP (DMX-1002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to the IMP (DMX-1002)
Study: NCT05085067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auto-crossed-linked hyaluronic acid gel
Description: infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
Study: NCT05715398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR790+anlotinib
Description: BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
Study: NCT05191810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational information
Description: Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
Study: NCT04933292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and Mycophenolate mofetil
Description: Methylprednisolone combination of mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone and azathioprine
Description: Methylprednisolone combination of azathioprine
Study: NCT06167486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG2918
Description: The SG2918 will be administrated by intravenous infusion every 3 weeks
Study: NCT05468502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cell injection
Description: Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
Study: NCT04774887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine, Merck
Description: Vaccination against HPV will be offered to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
Study: NCT05079386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Voice Prosthesis
Description: Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
Study: NCT06021808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic LAA clipping
Description: The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novel oral anticoagulant
Description: For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
Study: NCT04926116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK3280
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT05927116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD)
Description: TRIP is a mobile app-based intervention comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
Study: NCT05775900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
Study: NCT05372133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Children will be provided with morphine for at-home pain management following supracondylar fracture repair
Study: NCT05100979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Art of Medicine Series
Description: The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
Study: NCT06036199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound Pallidotomy
Description: Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
Study: NCT05882916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Description: Oral fluid-based HIV self-test kits for secondary distribution

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economic 'nudges'
Description: Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
Study: NCT06205433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IHSS Basic Training
Description: The intervention is the Center for Caregiver Advancements 30-hour IHSS Basic training course.
Study: NCT03605654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDR-102
Description: Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDR-102
Description: Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Agents
Description: Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
Study: NCT05613907

Intervention type: OTHER
Intervention: CLTI Clinic
Description: This is a specialist clinic designed to assess and manage patients with CLTI.

Intervention type: OTHER
Intervention: CLTI Clinic
Description: This is a specialist clinic designed to assess and manage patients with CLTI.
Study: NCT05968534

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MOSAIC Plus
Description: This is a single-arm study. Participants will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms.
Study: NCT04846231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
Study: NCT06505304

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood
Description: Blood will be collected at 3 and 6 months after surgery and used as standard of care. Research blood will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for research - i.e. proteomic, genomic, cell experiments (only in Irish sites).
Study: NCT04846231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
Study: NCT05782166

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Betel Quid Educational Booklet
Description: Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Betel Quid Educational Booklet
Description: Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour.
Study: NCT04992026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection
Description: Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.
Study: NCT06091748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC
Description: Detection of somatostatin positive lesions in GEP-NETs
Study: NCT04992026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.Abiraterone Acetate Tablets
Description: 1000mg(4 tablets, 250mg per tablet) daily for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.Abiraterone Acetate Tablets
Description: 1000mg(4 tablets, 250mg per tablet) daily for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone Acetate Tablets
Description: 5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Acetate Tablets
Description: 5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.
Study: NCT05018689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aevidum curriculum
Description: The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aevidum curriculum
Description: The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Club
Description: Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
Study: NCT05421676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)
Description: This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
Study: NCT05782166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Betel Quid Cessation Intervention Module
Description: All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour.
Study: NCT06241300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program
Description: Chicago Parent Program is an evidence-based group parenting intervention designed to reduce disruptive behavior in young children (2-8 years old).
Study: NCT05030584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elinzanetant (BAY3427080)
Description: 120 mg elinzanetant orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily.
Study: NCT06505304

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva
Description: Saliva will be collected during the visit of index colonoscopy and at 12 months after surgery for research - i.e. optical spectroscopy (only in Irish site)

Intervention type: OTHER
Intervention: Clinical follow-up
Description: Patients will be followed-up at 6, 12 and 24 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. The following scores will be repeated: Harvey Bradshaw Index (HBI) and CD Activity Index score (CDAI). Participants will give an update on their medication use.
Study: NCT06020885

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Split-course hypo-CCRT
Description: Split-course hypo-CCRT is administered at the following three dose levels:~* Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~* Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~* Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemo-immunotherapy
Description: All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
Study: NCT06033534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STIMULAN
Description: Procedures:~Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection.
Study: NCT06194305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBIT
Description: Participants will receive 8 sessions delivered weekly over 10 weeks. All sessions will be video recorded. CBIT components are: 1) Psychoeducation about tics, 2) Functional interventions, 3) Competing response (CR) training, 4) Social support: supportive people (e.g., parent, teacher) , 5) Motivational enhancements, 6) Homework: is assigned each session and typically involves self-monitoring and CR practice. Participants will complete a brief daily homework tracking log in REDCap.
Study: NCT05691387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thera PEP
Description: Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACBT and PLB
Description: On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
Study: NCT06184178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socio-health care
Description: Socio-health care under TEC-MED model and an integral assessment
Study: NCT05066412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
Description: CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
Study: NCT05285228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: effect of choice on cooperation (pseudoalternative)
Description: For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: given fluoride varnish (control)
Description: For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.